SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 3 2024 06:15:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 1 2024 20:58:03 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 1 2024 17:45:51 提供 Nasdaq GlobeNewswire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 12 2023 08:00:01 提供 Nasdaq GlobeNewswire